株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

マイクロバイオーム (微生物叢) の現状

The State of the Microbiome

発行 GlobalData 商品コード 787056
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
マイクロバイオーム (微生物叢) の現状 The State of the Microbiome
出版日: 2019年01月31日 ページ情報: 英文 39 Pages
概要

当レポートでは、世界のマイクロバイオーム (微生物叢) 市場について調査分析し、マイクロバイオームの投資、関連の課題、治療薬の開発・開始・製造について、体系的な情報を提供しています。

第1章 調査設計

第2章 エグゼクティブサマリー

第3章 マイクロバイオームの投資

  • 消化器病と感染症が最も活発な治療分野
  • 感染症と消化器病が最も投資の高い治療分野
  • マイクロバイオームパイプラインの詳細
  • マイクロバイオームパイプラインがターゲットにする胃腸病と感染症
  • マイクロバイオームパイプラインがターゲットにする胃腸病の詳細
  • マイクロバイオームパイプラインがターゲットにする感染症の詳細

第4章 マイクロバイオーム治療薬の開発における課題

  • 大きな課題は作用機序
  • 作用機序が最も困難な要因
  • 年功序列による詳細

第5章 マイクロバイオーム治療薬の立ち上げにおける課題

  • 大きな課題は製造
  • 製造が最も困難な要因
  • 年功序列による詳細

第6章 マイクロバイオーム治療薬の製造における課題

  • 用量処方が大きな課題

第7章 主な調査結果と提言

第8章 付録

目次
Product Code: GDHCHT021

Investment in Microbiome therapeutics is low across all therapy areas, but the infectious disease and gastrointestinal spaces are bringing in the highest levels of investment at 2.7 on a five-point scale. Identifying the mechanism of action was indicated by 27% of respondents as the most challenging aspect of developing Microbiome therapeutics. Also it is anticipated that the regulatory bodies may require drug developers to demonstrate the mechanisms of action of Microbiome therapeutics in order to gain regulatory approval.

Microbiome therapeutics was defined to include both live biotherapeutic products and products targeting the microbiome, excluding over the counter probiotics. As indicated, drug developers will face the challenge of manufacturing microbiome therapeutics using a cost-effective and scalable process that is consistent from batch to batch. Respondents indicated manufacturing (including consistency of strain) will be the most challenging aspect of launching microbiome therapeutics.

The report "The State of the Microbiome", provides an assessment of how the pharmaceutical industry perceives the state of the Microbiome, including the challenges associated with developing, launching, and manufacturing Microbiome therapeutics as well as where opportunity remains to invest in the Microbiome space.

The report is built on analyst expertise on the results of a 10 minutes survey of 158 Pharmaceuticals participants which was fielded from December 20, 2018 to January 7, 2019. Participants answered questions about the challenges they anticipate to impact the development, launch, manufacturing of Microbiome therapeutics.

Scope

  • Microbiome investment - determine level of activity and investment in the development of microbiome therapeutics by therapy area
  • Identify the challenges associated with
  • Developing microbiome therapeutics
  • Launching microbiome therapeutics
  • Manufacturing microbiome therapeutics.

Reasons to buy

  • Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with developing, launching and manufacturing microbiome therapeutics.
  • Develop business strategies by understanding the challenges associated with identifying and meeting regulatory requirments for the approval of microbiome therapeutics.
  • Identify where the opportunity remains to invest in the development of microbiome therapeutics.

Table of Contents

1 Study Design

  • 1.1 Background, Objectives, and Design
  • 1.2 Respondent Mix - Geography
  • 1.3 Respondent Mix - Seniority Level and Company Size

2 Executive Summary

  • 2.1 Executive Summary

3 Microbiome Investment

  • 3.1 Gastroenterology and Infectious Disease Mark the Most Active Therapy Areas
  • 3.2 Infectious Disease and Gastroenterology Most Highly Invested Therapy Areas
  • 3.3 A Closer Look at the Microbiome Pipeline
  • 3.4 Microbiome Pipeline Targeting Gastrointestinal Indications and Infectious Diseases
  • 3.5 A Closer Look at the Microbiome Pipeline Targeting Gastrointestinal Indications
  • 3.6 A Closer Look at the Microbiome Pipeline Targeting Infectious Diseases

4 Challenges with Developing Microbiome Therapeutics

  • 4.1 Identifying the Mechanism of Action Seen as a Major Challenge
  • 4.2 Identifying the Mechanism of Action Is Seen as the Most Challenging Factor
  • 4.3 A Closer Look by Seniority Level

5 Challenges with Launching Microbiome Therapeutics

  • 5.1 Manufacturing Identified as a Major Challenge
  • 5.2 Manufacturing Identified As the Most Challenging Factor
  • 5.3 A Closer Look by Seniority Level

6 Challenges with Manufacturing Microbiome Therapeutics

  • 6.1 Dose Formulation Is a Major Challenge

7 Key Findings and Recommendations

  • 7.1 Summary of Key Findings
  • 7.2 Recommendations

8 Appendix

  • 8.1 Related Reports
  • 8.2 Abbreviations
  • 8.3 Primary Research
  • 8.4 About the Authors
  • 8.5 About Thematic Research
  • 8.6 About GlobalData
  • 8.7 Contact Us
  • 8.8 Disclaimer
Back to Top